Regado Biosciences has a solid market debut despite Nasdaq's problems

|By:, SA News Editor

Cardiovascular treatment company Regado Biosciences (RGDO) finish the day solidly higher on its market debut after earlier pricing its 10.7 million share IPO at $4.

The offering differed significantly from its original plans. In early May the company disclosed plans to sell around 5M shares at $14 to $16 each. That was later revised to 8.4 shares priced at $5.

Trading has been caught up in the afternoon-long trading halt for the Nasdaq exchange, with just over 223,000 shares changing hands through mid-day before trading was suspended.

The shares traded as high as $5.39 each soon after the stock opened, seldom trading much below $4.80 a share.